share_log

Bone Biologics (OTC:BBLG) and Align Technology (NASDAQ:ALGN) Critical Survey

Bone Biologics (OTC:BBLG) and Align Technology (NASDAQ:ALGN) Critical Survey

骨生物制剂(场外交易代码:BBLG)和Align Technology(纳斯达克股票代码:ALGN)批判性调查
Defense World ·  2022/12/25 02:21

Bone Biologics (OTC:BBLG – Get Rating) and Align Technology (NASDAQ:ALGN – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Bone Biologics(场外交易代码:BBLG — 获取评级)和Align Technology(纳斯达克股票代码:ALGN — 获取评级)都是医疗公司,但哪种投资更好?我们将根据两家公司的机构所有权实力、分析师建议、估值、盈利能力、风险、股息和收益进行比较。

Valuation & Earnings

估值与收益

This table compares Bone Biologics and Align Technology's revenue, earnings per share (EPS) and valuation.

该表比较了Bone Biologics和Align Technology的收入、每股收益(EPS)和估值。

Get
获取
Bone Biologics
骨生物制剂
alerts:
警报:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bone Biologics N/A N/A -$1.61 million N/A N/A
Align Technology $3.95 billion 4.02 $772.02 million $6.47 31.48
总收入 价格/销售比率 净收入 每股收益 市盈率
骨生物制剂 不适用 不适用 -161 万美元 不适用 不适用
Align 技术 39.5 亿美元 4.02 7.7202 亿美元 6.47 美元 31.48

Align Technology has higher revenue and earnings than Bone Biologics.

Align Technology的收入和收益高于Bone Biologic

Volatility & Risk

波动性与风险

Bone Biologics has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Bone Biologics的beta值为0.11,这表明其股价的波动性比标准普尔500指数低89%。相比之下,Align Technology的beta值为1.65,这表明其股价的波动性比标准普尔500指数高65%。

Profitability

盈利能力

This table compares Bone Biologics and Align Technology's net margins, return on equity and return on assets.

该表比较了Bone Biologics和Align Technology的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Bone Biologics N/A 7,587.33% 7,258.20%
Align Technology 13.22% 14.39% 8.89%
净利润 股本回报率 资产回报率
骨生物制剂 不适用 7,587.33% 7,258.20%
Align 技术 13.22% 14.39% 8.89%

Analyst Ratings

分析师评级

This is a summary of recent recommendations for Bone Biologics and Align Technology, as provided by MarketBeat.

这是MarketBeat最近对Bone Biologics和Align Technology提出的建议的摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bone Biologics 0 0 1 0 3.00
Align Technology 1 0 7 0 2.75
卖出评级 保持收视率 买入评级 强劲的买入评级 评分分数
骨生物制剂 0 0 1 0 3.00
Align 技术 1 0 7 0 2.75

Bone Biologics currently has a consensus target price of $2.25, suggesting a potential upside of 971.43%. Align Technology has a consensus target price of $298.00, suggesting a potential upside of 46.32%. Given Bone Biologics' stronger consensus rating and higher probable upside, research analysts plainly believe Bone Biologics is more favorable than Align Technology.

Bone Biologics目前的共识目标价为2.25美元,这表明潜在的上涨空间为971.43%。Align Technology的共识目标价为298.00美元,这表明潜在的上涨空间为46.32%。鉴于Bone Biologics更高的共识评级和更高的可能上行空间,研究分析师显然认为Bone Biologics比Align Technologics更有利。

Insider and Institutional Ownership

内部所有权和机构所有权

7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 84.9% of Align Technology shares are owned by institutional investors. 71.5% of Bone Biologics shares are owned by insiders. Comparatively, 0.6% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bone Biologics的7.6%股份由机构投资者持有。相比之下,Align Technology的84.9%股份由机构投资者持有。71.5%的Bone Biologics股票由内部人士持有。相比之下,Align Technology的0.6%股份由内部人士持有。强大的机构所有权表明,对冲基金、捐赠基金和大型基金经理认为,从长远来看,股票的表现将超过市场。

Summary

摘要

Align Technology beats Bone Biologics on 6 of the 11 factors compared between the two stocks.

与两只股票相比,Align Technology在11个因素中有6个超过了Bone Biologics。

About Bone Biologics

关于 Bone Biologics

(Get Rating)

(获取评分)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Bone Biologics Corporation是一家医疗器械公司,专注于使用重组人蛋白在脊柱融合中的骨再生。该公司的NELL-1/DBX是一种组合产品,它是一种骨刺激性重组蛋白,可为骨再生提供靶向特异性控制。它正在开发 NELL-1/DBX 融合设备,用于治疗骨骼成熟的椎间盘退行性疾病患者,其水平与 L4-S1 相同。该公司的平台技术已应用于在脊柱、骨科、普通骨科、整形重建、神经外科、介入放射学和运动医学等外科专业领域提供增强的疗效。它与加州大学洛杉矶分校技术开发小组签订了许可协议,用于脊柱融合应用的 NELL-1 的开发和商业化。该公司成立于 2004 年,总部位于马萨诸塞州伯灵顿。

About Align Technology

关于 Align 科技

(Get Rating)

(获取评分)

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Align Technology, Inc. 是一家医疗器械公司,为正畸医生和全科医生牙医以及修复和美容牙科设计、制造和销售 Invisalign 透明牙套和iTero口内扫描仪和服务。它分为两个部分:Clear Aligner;以及扫描仪和服务。Clear Aligner细分市场由综合产品组成,包括满足青少年患者正畸需求的Invisalign综合治疗,例如下颌前进、顺应性指标和牙出补偿;以及针对通常年龄在七至十岁之间的年轻患者的Invisalign First I期和Invisalign First 综合阶段2套餐,该套餐包括原发牙/婴儿牙和恒牙。该细分市场的非综合产品包括Invisalign中度套餐、精简版和快捷套餐以及Invisalign go;非case产品包括保留产品、Invisalign培训费以及牙科专业人员在治疗过程中使用的清洁材料和调整工具等辅助产品的销售。扫描仪和服务部门提供iTero扫描仪,这是一个单一硬件平台,提供修复或正畸手术的软件选项;适用于全科牙医、口腔修复医生、牙周病医生和口腔外科医生的修复软件;以及供正畸医生使用的用于数字记录存储、正畸诊断以及制作印刷模型和保持器的软件。该部门还提供计算机辅助设计和计算机辅助制造服务;辅助产品,例如一次性魔杖套管;iTero模型和模具;第三方扫描仪和数字扫描;Invisalign结果模拟器,一种用于iTero扫描仪的椅旁和基于云的应用程序;Invisalign进展评估工具;以及TimeLapse技术,允许医生或从业人员将患者的历史三维扫描与当今的扫描进行比较。该公司在美国、瑞士、中国和国际上销售其产品。Align Technology, Inc. 成立于 1997 年,总部位于亚利桑那州坦佩。

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Bone Biologics 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Bone Biologics及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发